JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building

SHANGHAI, Jan. 9, 2022 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, recently announced the appointments of Dr. Shaun Paul Cordoba as Chief Scientific…